Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

a five-year survival rate of 40% for a disease would mean that 40% of people, or 40 out of 100 people, are alive five years after being diagnosed. Median survival is the amount of time at which 50% of ...

Adenocarcinoma grows in the tissue of the prostate gland, but other types of cancer can also start in the prostate or spread ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive ...

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC ... With SCLC, the 5-year survival rate is about 7%. Without treatment, survival is ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

Survival rates for lung cancer and other types of cancer are usually given as a five-year relative survival rate, which is ...

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive ...